Considering correlations between prolactin levels and concentrations of risk factors at baseline, cardiometabolic benefits of cabergoline therapy seem to be important from the clinical point of view, suggesting that postmenopausal women may benefit from cabergoline treatment, irrespectively of the presence of symptoms of prolactin excess. Here, PRL is linked to Increased circulating prolactin concentration.